Strategy and Efficacy of Generic and Pan-genotypic Sofosbuvir/Velpatasvir in Chronic Hepatitis C Virus: A Myanmar Experience

BACKGROUND: In resource-constrained areas, generic direct-acting antivirals (DAAs) have considerably reduced the cost of hepatitis C virus (HCV) therapy while there remain significant costs related to the baseline and follow-up virologic assays. AIM: The aim was to assess the efficacy and safety of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Exp Hepatol
Autors principals: Bwa, Aung H., Nangia, Gayatri, Win, Si T.S., Maung, Soe T., Han, Khin A.W., Htar, Su S., Wine, Lei Y., Ko, Wint W., Oo, Moe P., Hlaing, Naomi K.T., Palecki, Julia, Loza, Bao L., Win, Khin M., Reddy, Rajender
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2019
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6637231/
https://ncbi.nlm.nih.gov/pubmed/31360020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jceh.2018.12.001
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars